文献速递糖尿病肥胖与代谢综合征

胃束带术与二甲双胍对糖耐量受损或轻度2型糖尿病成人β细胞功能的影响

Impact of Gastric Banding Versus Metformin on β-Cell Function in Adults With Impaired Glucose Tolerance or Mild Type 2 Diabetes.
PubMed 文献 · Diabetes Care · 2018-10-03

结果显示两组在保留β细胞功能及稳定或改善血糖方面效果相似,胃束带术组体重下降更显著。

要点

  • 胃束带术与二甲双胍对β细胞功能的保护作用相似。
  • 胃束带术组体重下降10.7 kg,二甲双胍组1.7 kg(P<0.01)。
  • 两组24个月正常血糖比例分别为22%和15%(P=0.66)。

核心结论

  • 在中度肥胖伴糖耐量受损或新诊断轻度2型糖尿病成人中,胃束带术与二甲双胍在2年内对β细胞功能的保护及血糖稳定或改善效果相似。

研究设计与样本

  • 在基线、12个月和24个月进行高糖钳夹(11.1 mmol/L)后精氨酸注射(血糖>25 mmol/L)以测量稳态C肽、最大血糖 potentiation 下精氨酸急性C肽反应及胰岛素敏感性(M/I)。

主要发现

  • 24个月时胃束带术组体重下降10.7 kg,二甲双胍组下降1.7 kg(P < 0.01)。
  • 胰岛素敏感性在胃束带术组增加45%,二甲双胍组增加25%(组间P = 0.30)。
  • 经胰岛素敏感性校正的稳态C肽两组均轻微下降但无统计学意义(组间P = 0.34)。
  • 经胰岛素敏感性校正的ACPRmax在二甲双胍组显著下降(P = 0.002),胃束带术组无显著下降(组间P = 0.25)。
  • HbA1c在胃束带术组12和24个月均下降(P < 0.004),二甲双胍组仅12个月下降(P < 0.01)(组间P > 0.14);24个月正常血糖比例分别为22%和15%(组间P = 0.66)。

临床怎么用

  • 对于中度肥胖伴糖耐量受损或新诊断轻度2型糖尿病成人,胃束带术和二甲双胍均可作为保留β细胞功能和改善血糖的选择。
  • 胃束带术减重效果更显著,但需权衡手术风险与获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Type 2 diabetes (T2D) results from progressive loss of β-cell function. The BetaFat study compared gastric banding and metformin for their impact on β-cell function in adults with moderate obesity and impaired glucose tolerance (IGT) or recently diagnosed, mild T2D. RESEARCH DESIGN AND METHODS: Eighty-eight people aged 21-65 years, BMI 30-40 kg/m2, with IGT or diabetes known for <1 year, were randomized to gastric banding or metformin for 2 years. Hyperglycemic clamps (11.1 mmol/L) followed by arginine injection at maximally potentiating glycemia (>25 mmol/L) were performed at baseline, 12 months, and 24 months to measure steady-state C-peptide (SSCP) and acute C-peptide response to arginine at maximum glycemic potentiation (ACPRmax) and insulin sensitivity (M/I). RESULTS: At 24 months, the band group lost 10.7 kg; the metformin group lost 1.7 kg (P < 0.01). Insulin sensitivity increased 45% in the band group and 25% in the metformin group (P = 0.30 between groups). SSCP adjusted for insulin sensitivity fell slightly but not significantly in each group (P = 0.34 between groups). ACPRmax adjusted for insulin sensitivity fell significantly in the metformin group (P = 0.002) but not in the band group (P = 0.25 between groups). HbA1c fell at 12 and 24 months in the band group (P < 0.004) but only at 12 months (P < 0.01) in the metformin group (P > 0.14 between groups). Normoglycemia was present in 22% and 15% of band and metformin groups, respectively, at 24 months (P = 0.66 between groups). CONCLUSIONS: Gastric banding and metformin had similar effects to preserve β-cell function and stabilize or improve glycemia over a 2-year period in moderately obese adults with IGT or recently diagnosed, mild T2D.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Xiang AH, Trigo E, Martinez M, et al. Impact of Gastric Banding Versus Metformin on β-Cell Function in Adults With Impaired Glucose Tolerance or Mild Type 2 Diabetes. Diabetes Care. 2018. PMID: 30282699. doi:10.2337/dc18-1662

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。